Beyond Air's stock price fell 8.14% as it crossed below the 5-day SMA amid mixed market conditions.
The company has entered into an agreement to sell 85% of its subsidiary NeuroNOS to XTL Biopharmaceuticals, which includes 19.9% of XTL's shares, $1 million in cash, and up to $32.5 million in milestone payments. This strategic move is aimed at enhancing Beyond Air's focus on its core operations while providing funding for NeuroNOS's development in autism and neuro-oncology treatments. The deal is expected to validate the scientific foundation of NeuroNOS and create significant value for shareholders.
This transaction positions Beyond Air to streamline its operations and potentially enhance shareholder value, despite the current stock decline.
Wall Street analysts forecast XAIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XAIR is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast XAIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XAIR is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.270
Low
6.00
Averages
6.00
High
6.00
Current: 1.270
Low
6.00
Averages
6.00
High
6.00
Rodman & Renshaw
NULL -> Buy
initiated
$5
2026-01-20
Reason
Rodman & Renshaw
Price Target
$5
AI Analysis
2026-01-20
initiated
NULL -> Buy
Reason
Rodman & Renshaw initiated coverage of Beyond Air with a Buy rating and $5 price target.
Piper Sandler
Overweight
downgrade
$20 -> $5
2025-08-13
Reason
Piper Sandler
Price Target
$20 -> $5
2025-08-13
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Beyond Air to $5 from $20 and keeps an Overweight rating on the shares following quarterly results. The firm says that the incremental updates are modest, with management reiterating confidence in its $12M-$16M revenue guidance and referenced multiple areas that could serve as the necessary FY26 catalysts.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for XAIR
Unlock Now
D. Boral Capital
Jason Kolbert
initiated
$11
2025-07-17
Reason
D. Boral Capital
Jason Kolbert
Price Target
$11
2025-07-17
initiated
Reason
D. Boral Capital analyst Jason Kolbert initiated coverage of Beyond Air with a Buy rating and $11 price target. The firm says the company's LungFit platform represents a "disruptive leap" in nitric oxide delivery. It enables on-demand generation from ambient air without the need for high-pressure gas cylinders or chemical cassettes, the analyst tells investors in a research note. Boral believes new indications represent out-year revenue drivers for Beyond Air.
About XAIR
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
